The Grapefruit Warning and CBD

Plain-language summary

Grapefruit juice carries a warning on many prescription drugs because compounds in it (furanocoumarins) block CYP3A4, a liver enzyme that breaks down a huge fraction of medications. When the enzyme is blocked, the drug builds up in your blood — sometimes to toxic levels.

CBD does something similar. In lab studies and in humans, CBD inhibits CYP3A4, CYP2C9, CYP2C19, and several other CYP and UGT enzymes Strong evidence ^[1][2]. That means CBD can raise blood levels of drugs metabolized by those enzymes, the same way grapefruit does — and sometimes more strongly.

The practical shortcut: if your medication bottle says 'avoid grapefruit,' treat CBD with the same caution. It is not a perfect overlap, but it is a useful first filter.

What probably works (well-established interactions)

Clobazam (Onfi) — CBD substantially raises levels of N-desmethylclobazam, the active metabolite. Documented in pediatric epilepsy trials at doses around 20 mg/kg/day; many children needed clobazam dose reductions Strong evidence ^[3][4].

Warfarin — Case reports show INR increases when CBD is added. CBD inhibits CYP2C9, which metabolizes the more potent S-warfarin enantiomer Strong evidence ^[5].

Tacrolimus — A documented case showed CBD roughly tripled tacrolimus trough levels at high doses Strong evidence ^[6].

Valproate — Co-administration with CBD increases the risk of elevated liver enzymes, though the mechanism is not purely pharmacokinetic Strong evidence ^[3][4].

Other antiepileptics — Topiramate, rufinamide, zonisamide, and eslicarbazepine levels have all been shown to rise with CBD co-administration in epilepsy trials Strong evidence ^[7].

These are the interactions the FDA references in the Epidiolex prescribing information. They are not folklore.

What might work (plausible but less data)

Statins — Simvastatin and atorvastatin are heavily CYP3A4-dependent and carry the classic grapefruit warning. CBD plausibly raises their levels and the risk of muscle toxicity, but human data are limited to in vitro and pharmacokinetic modeling Weak / limited ^[2][8].

SSRIs and other psychiatric drugs — Sertraline, citalopram, and others metabolized by CYP2C19 or CYP3A4 could see modest level increases. A handful of case reports exist. Clinically relevant in some patients, probably not in most Weak / limited.

Benzodiazepines beyond clobazam — Diazepam, alprazolam, and midazolam are CYP3A4 substrates. Interaction is biologically plausible; controlled data in humans on CBD are thin Weak / limited.

Direct oral anticoagulants (DOACs) — Apixaban and rivaroxaban are CYP3A4/P-gp substrates. Case reports of bleeding exist; controlled studies do not Weak / limited ^[9].

What doesn't work or has weak evidence

The 'CBD is natural so it's safe' claim — false. Natural compounds can be potent enzyme inhibitors. Grapefruit is also natural No data.

The idea that topical CBD interacts with oral medications — overwhelmingly unlikely. Systemic absorption from topicals is very low Weak / limited.

Claims that 'full-spectrum' CBD avoids interactions because of the entourage effect — no evidence supports this. Full-spectrum products still contain CBD, often at the same doses, and still inhibit CYP enzymes No data.

The notion that microdoses (5–10 mg/day) cause clinically meaningful interactions — possible but not well documented. Most interaction data come from doses above 100 mg/day. Low-dose users on a single non-critical medication are probably at low risk Weak / limited.

What we don't know

• The dose-response curve for CBD-drug interactions below ~10 mg/kg/day is poorly mapped. Most rigorous data come from Epidiolex trials at 10–20 mg/kg/day.
• Whether inhaled CBD (which bypasses first-pass metabolism) produces a different interaction profile than oral CBD.
• How CBD interacts with most of the top 100 prescribed drugs in the U.S. — we have systematic data for perhaps a few dozen.
• Whether genetic CYP variants (poor vs. extensive metabolizers) change the interaction magnitude meaningfully. Plausible, but unstudied.
• The clinical significance of CBD's effects on UGT enzymes, which handle drugs like lamotrigine and morphine.

Comparison with standard practice

Pharmacists routinely screen prescriptions for CYP3A4 interactions. The infrastructure to handle CBD already exists — clinicians just need to know to enter it. Many EHR drug-interaction checkers now flag CBD; not all do.

For patients, the standard 'grapefruit list' published by hospitals and pharmacy schools is a reasonable proxy. The Food and Drug Administration's Epidiolex label ^[3] and the indiana.edu Flockhart Table on CYP-mediated interactions ^[10] are the two most useful free references.

Compared to grapefruit, CBD's enzyme inhibition is generally:

• Longer-lasting (grapefruit's effect wears off over 24–72 hours; CBD with daily dosing produces sustained inhibition).
• Broader (CBD hits more enzymes than just CYP3A4).
• Dose-controllable (you choose your CBD dose; grapefruit serving sizes vary).

Risks and practical guidance

Realistic risk categories:

• High risk — narrow-therapeutic-index drugs: warfarin, tacrolimus, cyclosporine, clobazam, certain chemotherapeutics, immunosuppressants. Don't add CBD without your prescriber knowing.
• Moderate risk — statins, SSRIs, antipsychotics, opioids metabolized by CYP3A4 (fentanyl, oxycodone), DOACs. Worth a conversation.
• Low risk — drugs not metabolized by CYP450 (e.g., lithium, gabapentin, metformin, levothyroxine). Interaction unlikely.

Practical steps if you take prescription medication:

1. Check whether your drug has a grapefruit warning. If yes, treat CBD as the same category of risk.
2. Ask your pharmacist — they are usually the most accessible interaction expert.
3. If you and your clinician decide CBD is worth it, start low, go slow, and consider checking drug levels (INR for warfarin, trough levels for tacrolimus, etc.) after starting.
4. Tell every clinician you see that you use CBD. They cannot screen for what they don't know about.

---

This is not medical advice. This article summarizes published evidence for general education. Drug interactions depend on your specific medications, doses, liver function, genetics, and other factors. Talk to a pharmacist or physician before combining CBD with prescription drugs. Do not stop or change a prescribed medication based on anything you read here.

Sources

How this page was made